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Summary 
Eleven patients with osteoarthritis and mild hypertension completed an 8-week, 
double-blind crossover study in which 200 mg tiaprofenic acid 3-times daily or 
placebo were substituted for their normal non-steroidal anti-inflammatory therapy. 
Systolic blood pressure was significantly higher on tiaprofenic acid therapy than on 
placebo and plasma renin activity was significantly lower on active treatment. No 
significant changes were seen in biochemical parameters, though the weight of the 
patient was also higher on tiaprofenic acid than on placebo. Duration of morning 
stiffness was also lower on tiaprofenic acid than on placebo. Blood pressure on 
tiaprofenic acid was not different from baseline readings on other non-steroidal anti-
inflammatory drug therapy. This study suggests that tiaprofenic acid, like other non-
steroidal anti-inflammatory agents, may interfere with blood pressure control in 
treated hypertensive patients. 
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I n t r o d u c t i o n  
Tiaprofenic acidg is a new non-steroidal anti-inflammatory drug which has signifi-
cant anti-inflammatory and analgesic effects in animal models of inflammation.5 
Pharmacokinetic studies demonstrate rapid absorption from the gastro-intestinal 
tract with a relatively short plasma elimination half-life of about 2 hours.13 
Treatment for 2 weeks failed to demonstrate any significant accumulation or 
alteration in biotransformation.4 A number of short-term controlled clinical trials 
conducted  in  patients  with  rheumatoid arthritis  and  osteoarthritis 1, 16, 20  have 
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